The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Informa
Skip to Page Content

Full Deal Summary

Jiangsu Alphamab Biopharmaceuticals Co. Ltd. (Alphamab Oncology) raised over $100mm in its Series A financing to Advantech Capital, PAG, China Venture Capital Fund, OrbiMed, Heritage Provider Network, and Janchor Partners.

The company plans to use the funds for pipeline development (especially a second-generation immuno-oncology candidate), to expand its clinical and commercial teams, and finish development of new biologics manufacturing facilities. In 2016, Alphamab Oncology gained the cancer pipeline of Suzhou Alphamab. Included in that deal was PD-L1 inhibitor KN035 (envafolimab) currently in pivotal trial in China; KN046, a PD-L1/CTLA-4 bispecific antibody in a Phase I trial in Australia with multiple Phase I/II trials planned in China; KN026, an anti-HER2 bispecific antibody in a Phase I China study and which recently got IND approval; and the immunomodulator KN019 expected to enter Phase II in China in H1 2019.


+ Show All | – Hide All

Financials


Click a figure for comparable deals.

Overview
Potential Deal Value $100.00mm
Transactions 1 of 1 (11/2018)
Round # 1
Funding Stage Additional Round
Equity $100.00mm
Total Line Value $100.00mm
Gross Proceeds $100.00mm
Investors Advantech Capital
OrbiMed Advisors LLC
Softbank China Venture Capital

Deal Information


Click a keyword for comparable deals.

Deal Industry Biotechnology
Large Molecule
Antibodies
Pharmaceuticals
Deal Status Final
Deal Type Financing
Private Placement

Company Information


Click a keyword for comparable companies.

Jiangsu Alphamab Biopharmaceuticals Co. Ltd. http://www.alphamabonc.com
View Company Profile | View Company Deals
Company Location Worldwide
Asia
China
Industry Biotechnology
Large Molecule
Antibodies
Pharmaceuticals
Description Start-Up
Ownership Private
Therapeutic Area(s) of Focus Cancer
Immune Disorders